跳至主要内容
临床试验/NL-OMON22392
NL-OMON22392Other不适用

The effect of body weight on trough concentrations of DOACs in patients.

Haga Teaching Hospital and Central Hospital Pharmacy The Hague0 个研究点目标入组 160 人开始时间: 待定最近更新:

试验速览

阶段
不适用
状态
Other
发起方
入组人数
160

研究概览

简要总结

/A

研究设计

研究类型
Observational

入排标准

入选标准

  • Male or female ≥ 18 years
  • - Treated with a DOAC (rivaroxaban, dabigatran, apixaban, edoxaban) in a therapeutic or prophylactic dosage for at least 5 days

排除标准

  • - The use of relevant co-medication: Ketoconazole, Posaconazole, Voricanazole , Itraconazole , Fluconazole, HIV protease inhibitors, Ticagrelor , Verapamil , Diltiazem (except dabigatran) , Amiodarone , Quinidine, Cyclosporin, Tacrolimus, Clarithromycin, Erythromycin, Carbamazepine, Rifampicin, St John¡¯s wort, Phenytoin
  • phenobarbital

研究者

发起方
Haga Teaching Hospital and Central Hospital Pharmacy The Hague

相似试验

The effect of body weight on the medicine... | 临床试验